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The mechanism by  which the  platelet-derived 
growth  factor (PDGF)-binding protein, a2-macroglob- 
ulin (azM), modulates  PDGF  bioactivity is unknown, 
but could involve reversible PDGF-azM  binding. 
Herein  we  report that >70% of ‘”I-PDGF-BB or -AB 
complexed to azM  was dissociated  by SDS-denatura- 
tion followed by SDS-polyacrylamide  gel  electropho- 
resis, i.e. most of the  binding  was noncovalent. Reduc- 
tion of the  PDGF*azM complex following denaturation 
dissociated the  cytokine  from azM by >go%, suggesting 
covalent  disulfide bond formation.  Approximately 50% 
of the  growth  factor  was dissociated by lowering the 
pH from 7.5 to 4.0. 12’I-PDGF-BB bound azM in a 
time-dependent manner (tllz = -1 h), reaching equilib- 
rium  after 4 h. The ‘”I-PDGF*BB/a2M complex dis- 
sociated  more  slowly (tllz = -2.5 h). “Slow” and  “fast” 
azM bound nearly  equal  amounts of PDGF-AB or -BB. 
Trypsin  treatment  converted PDGF-BB/azM complex 
to  the  fast  conformation  but  did not  release  bound “‘I- 
PDGF-BB. All PDGF-isoforms (AA, -AB, and -BB) 
competed for  binding  with ‘”I-PDGF-BB binding  to 
slow cuzM and  fast  azM-methylamine  by 65430%. Other 
cytokines  that  bind aZM (transforming  growth  factor- 
81 and -82, tumor  necrosis  factor-a,  basic  fibroblast 
growth  factor,  interleukin-18,  and -6) did  not  compete 
for “‘I-PDGF-BB binding slow azM, but  transforming 
growth factor-81 and basic fibroblast growth factor 
inhibited ‘“I-PDGF-BB binding  a2M-methylamine by 
3040%. The  reversible  nature of the PDGF-aZM com- 
plex could allow for  targeted  PDGF  release  near mes- 
enchymal  cells  which possess PDGF  receptors. 
Platelet-derived growth factor (PDGF)’ and PDGF-like 
factors secreted by smooth muscle cells (l), endothelial cells 
(2), monocytes (3, 4), and macrophages (4-6) are potent 
mitogens and  chemoattractants for cells of mesenchymal or- 
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igin. Numerous studies that implicate PDGF  as a key media- 
tor  in  the normal processes of development, tissue  mainte- 
nance, and wound healing have been reviewed (7). PDGF has 
also been proposed as a link in  the progression of diseases 
such as atherosclerosis (8) and pulmonary fibrosis (9, 10). 
Two different monomeric chains of PDGF (A and  B) give rise 
to three possible dimers (AA, AB, BB), and these dimeric 
isoforms recognize dimeric cell-surface receptors composed of 
a and/or @ chains (11). PDGF isoforms recognize their recep- 
tors according to a receptor subunit model, i.e. AA, AB, BB 
dimers  bind to aa receptors; BB, AB dimers to a@; and  the 
BB dimer to p@ receptors (12). The different subtypes of 
PDGF and receptors could allow for a fine tuning of cell 
responsiveness, since different cell types can vary greatly in 
the ratio of isoforms secreted and in the receptor composition 
which the target cell possesses (13). Cell responsiveness to 
PDGF in uitro can be further modulated by other growth 
factors such as  TGF-@ (14) and by PDGF-binding proteins 
(15). 
The major PDGF-binding  protein is az-macroglobulin 
(aZM)  and  PDGF- a2M complexes have been isolated from 
plasma and from macrophage supernatants (16-19). This 725- 
kDa protein apparently serves mutiple functions as a cyto- 
kine-binding  protein  (20), wide spectrum  proteinase  inhibitor 
(21-25), and immune regulator (26, 27). azM was first de- 
scribed as a  proteinase  inhibitor and  the mechanism whereby 
native or electrophoretically “slow” azM covalently entraps 
proteinases has been extensively studied (see Ref. 25 for 
review). A proteinase cleaves azM in its “bait region,” and 
this cleavage induces a conformational change in the aZM 
molecule which entraps  the proteinase. The conformational 
change makes the azM more compact and hence has greater 
mobility on  nondenaturing gel electrophoresis than  the native 
or slow form of azM.  The irreversible triggering of the pro- 
teinase trap is mimicked by primary amines (28), and the 
electrophoretically “fast”  a2M-proteinase or azM-amine com- 
plex is receptor-recognized by fibroblasts (29, 30) and mac- 
rophages (31-34). PDGF binds  both slow and fast forms of 
azM (15), and PDGF-stimulated fibroblast proliferation (15) 
and chemotaxis (35) are inhibited by  slow a2M. azM inhibits 
the binding of PDGF to its cell-surface receptor and  thus  has 
been suggested to limit the amount of PDGF  that is available 
to bind to these  receptors (16). On the other  hand, methyla- 
mine-modified, fast, azM synergistically enhances the growth 
promoting  activity of human  PDGF purified from platelets 
(15). Thus,  aZM modulates the biological activities of PDGF 
in uitro. It  has been speculated that  a2M could serve mutiple 
functions as a  PDGF-binding  protein in uiuo (16), including 
1) modulation of PDGF biological activity as discussed above, 
2) protection of PDGF against proteolytic degradation, and 
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3) clearance of PDGF from the circulation. 
a2M also binds and modulates the biological activities of 
several other growth promoting cytokines, including trans- 
forming growth factor-@ (TGF-@) (36-42), tumor necrosis 
factor-a  (TNF-a) (43), basic fibroblast growth factor  (bFGF) 
(44), interleukin-l@ (IL-l@) (45), interleukin-6 (IL-6) (46), 
nerve growth factor (47) and human growth hormone (48). 
The biological activity of some of these cytokines is inhibited 
when bound to a 2 M ,  as is the case with TGF-@ (42). Others 
such  as IL-6  (46) and  PDGF (15, 18) retain biological activity 
when complexed to  this binding protein. While it is becoming 
increasingly apparent  that a  number of different  cytokines 
utilize a2M as a binding protein, the sites  on the azM molecule 
to which these  factors  bind could differ. Determining  whether 
or not  these different cytokines compete for the same  binding 
site(s) on this protein could be important in discerning the  in 
uiuo effects of a z M  as a potential modulator of cytokine 
activity. This is likely since many cell types (e.g. macrophages) 
secrete mixtures of these  cytokines and a z M  (49). Also, it  has 
been suggested that these cytokines bind a2M either cova- 
lently, noncovalently, or via a  mixture of covalent and  non- 
covalent associations (see Ref. 20 for review). 
PDGF has been reported to bind a Z M  covalently (17, 18). 
However, other studies suggest that  at least part of the  PDGF 
is noncovalently bound, since it can be released by 1 M acetic 
acid treatment (16,19). Thus,  the  first objective of the present 
study was to establish the ratio of covalent/noncovalent bind- 
ing of PDGF to a2M slow and fast forms. The issue of 
reversible binding is of paramount importance if one is to 
elucidate the mechanism(s) by which this binding protein 
modulates PDGF activity. Furthermore, such information 
may reconcile the  apparent differences that currently  exist in 
the literature regarding covalent and noncovalent associations 
between PDGF and a2M (16-19). Second, because only PDGF 
purified from platelets has been reported to bind a z M ,  it is 
not known if one or all of the  three different PDGF isoforms 
(AA, AB, BB) bind to a similar site on the a Z M  molecule. 
Thus, we sought to establish the competition of these isoforms 
for  lZ5I-PDGF-BB binding to a z M .  Third, since several other 
cytokines bind a z M ,  it is of major importance to determine 
the possible competitive nature of these factors for PDGF 
binding to a 2 M .  Herein, we report that  the majority of PDGF 
binding to slow or fast aZM is reversible or noncovalent, and 
that all PDGF isoforms compete for a  similar site on a Z M ,  
MATERIALS AND  METHODS 
Growth Factors and anM-Human PDGF purified from platelets, 
TGF-01, and TGF-/32  were purchased from R & D Systems (Minne- 
apolis, MN). PDGF-AA,  -AB, and -BB isoforms, bFGF, TNF-a, IL- 
lp, and IL-6 were obtained from Upstate Biotechnology (Lake Placid, 
NY). Human anM was purchased from Calbiochem (San Diego,  CA) 
and bovine plasma aZM was obtained from Boehringer Mannheim. 
Conversion of aaM from Slow to  Fast-All  azM preparations were 
subjected to dialysis against 100 volumes of distilled water to precip- 
itate fast anM, which  was present to some extent in all preparations. 
The native apM was tested for trypsin binding activity as described 
below. Slow anM was converted to fast a2M by incubation with 25 
mM methylamine (Tris-HC1, 50 mM, pH 8.0) overnight at 25 "C or 
by incubation with a 4:l molar excess of trypsin or plasmin for 30 
min at room temperature. Excess methylamine was removed from 
tu,M-methylamine  complexes by dialysis against 100  volumes of 50 
mM Tris-HC1, pH 8.2, at 4 "C. Excess trypsin or plasmin was removed 
from azM-trypsin or anM-plasmin complexes by  gel filtration chro- 
matography (Superose 6  FPLC). Fast  azM preparations were stored 
at 4 "C in 50 mM Tris,  pH 8.2, to prevent precipitation. Slow azM 
was stored at 4 "C in 20 mM sodium citrate buffer, pH 6.5. a2M 
preparations were tested for PDGF  contamination  as described pre- 
viously (15). 
Trypsin Binding Assay for apM-Native azM was tested for trypsin 
binding activity by a modification of a previously described method 
(50). Increasing concentrations of aZM were added to 96-well micro- 
titer plates to a final volume of 50  pl/well in 25 mM Tris-HC1, 150 
mM NaCI, pH 7.4. 3 pl/well of 1 mg/ml trypsin (Sigma) was then 
added for 10 min to bind available native azM, followed by the 
addition of 6 pl/well of 1 mg/ml soybean trypsin  inhibitor (Sigma), 
which inhibited all  trypsin activity not bound to aZM. After 10 min, 
80 pl/well of  0.1 M Tris-HCI,  10 mM CaClZ buffer, pH 8.0, was added, 
followed immediately by 100  pl/well 3 mM Na-benzoyl-DL-arginine- 
p-nitroanilide (BAPNA) hydrochloride (Sigma). The colorimetric 
reaction was stopped by the addition of 10 pl of glacial acetic acid. 
The increase in the optical density read at 405 nm is proportional to 
the quantity of active trypsin (covalently trapped within a2M) avail- 
able to convert the BAPNA substrate to  its product. 
Gel Filtration Chromatography-PDGF. a2M complexes were rou- 
tinely prepared by incubating 1 ng of human 'T-PDGF-AB or human 
recombinant lZ5I-PDGF-BB with 100 pg  of azM fast or  slow form for 
24 h at  37 "C. These mixtures were isolated by loading onto a gel 
filtration, molecular weight exclusion column (Superose 6 FPLC, 
Pharmacia  LKB Biotechnology Inc.) equilibrated in phosphate-buff- 
ered saline, pH 7.5, operating at  a flow rate of 0.5 ml/min. The 
column was standardized with the following molecular mass markers: 
aprotinin (6.5 kDa), cytochrome c (12.4 kDa), carbonic anhydrase (29 
kDa), bovine serum albumin (66 kDa), &amylase (200 kDa), apofer- 
ritin (440 kDa), thyroglobulin (669 kDa), and blue dextran (Vo). 
Fractions (1 ml) were counted on a  y-counter to measure radiolabeled 
PDGF or assayed for anM by ELISA as described below. Protein was 
routinely measured by absorbance (280 nm)  to ensure that identical 
amounts of PDGF/a2M were loaded onto  the column. 
Gel Electrophoresis-Electrophoresis of the PDGF/azM mixtures 
in a  nondenaturing  (5%  Tris-borate) gel  was performed as described 
previously (51). azM that was incubated with lZ5I-PDGF-AB or -BB 
as described above for gel filtration chromatography was  mixed with 
Tris-borate buffer (10 pg  of azM in 40 pl added to 4 pl of 10 X buffer 
with 10 p1 of glycerol) and electrophoresed on a native 5% gel. Native 
gels  were either  stained with Coomassie Blue and dried for autoradi- 
ography or transferred to nitrocellulose, blocked with 5% BSA for 2 
h, then shaken with 1:2000 sheep anti-human  azM-horseradish per- 
oxidase (Vector Laboratories) in BSA/PBS-Tween for 4  h and devel- 
oped. For SDS-polyacrylamide gel electrophoresis 80 pl (20 pg) 
PDGF/a2M samples were  mixed with an equal volume of 10% SDS 
and heated to 37 "C for 1 h, and half of each resulting sample received 
10% 2-mercaptoethanol. Samples were run  on  a 7.5% SDS gel. The 
gels  were stained with Coomassie Blue and dried for autoradiography 
and y-counting. 
azM ELISA-We  developed an enzyme immunoassay for human 
aaM using Immulon 2 Removawell flat-bottomed wells (Dynatech, 
Chantilly, VA) which were coated 100 pllwell with a 1:lOOO dilution 
of rabbit anti-azM in PBS (DakoPatts, Santa Barbara, CA) and 
incubated overnight a t  4 "C. The following day, the wells  were washed 
five times with PBS containing 0.05% Tween-20 (PBST)  and  then 
200 pllwell of 1% BSA in PBS was added. After a  5-h incubation at 
4 "C, the wells  were washed five times with PBST,  and 100  pl/well of 
standard a2M or unknown sample diluted in 1% BSA-PBS were 
added and incubated overnight at 4 'C. Zero antigen controls and 
horseradish peroxidase-antibody blanks received only 1% BSA-PBS. 
The following day, the plate was washed five times with PBST  and 
100 pllwell of horseradish peroxidase-conjugated, sheep anti-human 
azM (Serotec, Kidlington, Oxford, United Kingdom) diluted in 1% 
BSA-PBS (1:5000)  was added and incubated at room temperature for 
5 h. After washing five times with PBST,  the wells  were  developed 
for 15-30 min with the diammonium salt of 2,2'-azinobis-3-ethylben- 
zothiazoline-6-sulfonic acid (Sigma) containing 0.003%  hydrogen per- 
oxide. The absorbance (405 nm) was measured on  a  Titertek Multis- 
kan 96-well plate reader (Flow Laboratories, Mclean, VA). Doubling 
dilutions of anM (2-1000 ng/ml) were used, and  the linear range of 
the curve was between 5-500 ng/ml. 
RESULTS 
Isolation of PDGF.azM Complexes by Gel Filtration Chro- 
matography-To establish the elution profile of the  PDGF. 
a z M  complex, human  lz5I-PDGF-AB was incubated with hu- 
man a z M  in Ham's F-12 buffer with HEPES, CaCL, and 
0.25%  BSA (binding buffer) at  pH 7.4 and  the mixture was 
loaded onto a Superose 6 FPLC column equilibrated in PBS 
at  the same  pH. Later experiments were designed to study 
the formation of this complex on the same column and  the 
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subsequent dissociation of human PDGF-AB or recombinant 
PDGF-BB from human  or bovine a2M  following a decrease 
in  the  pH of the binding buffer. A  separate  series of experi- 
ments addressed the formation of the  PDGF.a2M complex 
on this column in the absence or presence of the three 
recombinant human PDGF isoforms or several other cyto- 
kines (TGF-8, bFGF, IL-18, IL-6, TNF-a) that have been 
reported to bind to  a2M.  Human  a2M eluted as single peak as 
measured by ELISA and  the major peak of human "'1-PDGF- 
AB coeluted with this immunoreactive apM  (Fig. 1). 
Binding of PDGF to Slow and Fast a2M-Isolation of the 
''1 - PDGF-AB - a2M complex by nondenaturing gel electro- 
phoresis was performed to demonstrate the purity of slow and 
fast  a2M preparations and  to establish the  amount of human 
plasma-derived 12'I-PDGF-AB bound to these  forms of  a2M. 
Both purified forms of slow human a2M and  fast methyla- 
mine-modified a2M bound human "'I-PDGF-AB  (Fig. 2A). A 
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FIG. 1. Binding of human slow azM to human "'1-PDGF 
purified from platelets. 100 pg of a2M was mixed with 1 ng of "'I- 
PDGF-AB in 500 pl of binding buffer and incubated for 1 h a t  37 "C 
prior to loading on a Superose 6 FPLC column. "'1-PDGF (open 
circles) coeluted with  a single peak of a2M (closed circles) that was 
measured by ELISA. The  a2M was quantified based on a standard 
curve (inset) generated  with the same  human a2M that was present 
in the PDGF-AB.a2M complex. Arrows indicate molecular mass 
markers, 1, blue dextran ( Vo); 2, thyroglobulin (669 kDa); 3, apofer- 
ritin (440 kDa); 4, @-amylase (200 kDa); 5, BSA (66  kDa); 6, carbonic 
anhydrase (29 kDa); and 7, cytochrome c (12.4 kDa). 
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FIG. 2. Binding of methylamine-treated and untreated slow 
human crzM to  human l29-PDGF-AB purified from platelets. 
Slow ( Y ~ M  was modified by methylamine as described under  "Mate- 
rials  and Methods." '"1-PDGF-AB (1 ng) was mixed 100 pg  of human 
slow a2M  or a2M-methylamine in 500 pl of binding buffer. 10 pg  of 
the 12'II-PDGF-AB/a2M mixture was loaded onto a  nondenaturing 5% 
Tris-borate gel and electrophoresed to demonstrate fast (F) a2M- 
methylamine and slow ( S )  a2M migration. Complexes of "'I.PDGF. 
cu2M were transferred to nitrocellulose. Panel A ,  Western  blot of slow 
(YZM (lane 1 )  and methylamine-modified a2M (lane 2) using  a  rabbit 
anti-human  a2M horseradish peroxidase-conjugated antibody and  the 
corresponding  autoradiograph of  "'I-PDGF bound to slow a2M (lane 
3) and a2M-methylamine (lane 4 ) .  Panel B, quantitation of bound 
"'I-PDGF-AB in slices of nitrocellulose from the  same experiment 
shown in panel A as determined by y-counting. S and F represent 
slow aBM (open  circles) and a2M-methylamine (closed circles), respec- 
tively. 
quantitative analysis of the 12'I-PDGF-AB bound to these 
a2M forms showed that approximately equivalent amounts of 
PDGF bound either the  fast  or  the slow form (Fig. 2B). 
Preferential Noncoualent Binding of PDGF to azM-To 
measure the  extent of covalent or noncovalent binding of  "'I- 
PDGF-AB to native a2M,  the I2'I.PDGF-AB .anM complex 
was subjected to SDS denaturation or 2-mercaptoethanol 
reduction prior to SDS-polyacrylamide gel electrophoresis. As 
expected, SDS  treatment dissociated the  a2M molecule into 
its -180-kDa subunits as determined by protein  staining and 
autoradiography of 12'I-a2M-methylamine (Fig. 3) .  No "'I- 
PDGF-AB was initially detected by autoradiography at  the 
molecular weight of this  a2M subunit (Fig. 3A). Instead, the 
l2'1-PDGF-AB  was detected at  the molecular mass of the -30- 
kDa PDGF dimer (SDS  treatment)  or  the -15-kDa PDGF 
monomer following reduction. However, a longer exposure of 
the SDS-denatured 12'I-PDGF-AB. a2M complex  revealed a 
minor autoradiographic signal, indicating that some PDGF 
remained covalently bound to  the  a2M (Fig. 3B). The same 
experiments were performed with recombinant 12'I-PDGF- 
BB. y-Counting the  intact "'I-PDGF-BB . a2M complex  from 
the nondenaturing gels and  the  a2M  subunits from denatured 
or reduced SDS gels (Fig. 4) demonstrated that 20-30% of 
the "'I-PDGF-BB remained bound to the denatured a2M 
subunit and less than 10% of the '2sI-PDGF-BB remained 
bound to  the binding protein subunits after reduction (Fig. 
4). Similar  results were obtained for bovine "'1-PDGF-BB. 
a2M complex. 









FIG. 3. Effect of denaturation and reduction on the human 
'261.PDGF-AB .azM complex and '261-azM-methylamine. Hu- 
man slow  a2M (100 pg)  was incubated with "'1-PDGF-AB (1 ng) in 
500 pl of binding medium, pH 7.4, and incubated for 1 h at 37 "C and 
then  treated with either 7.5% SDS  or 10% 2-mercaptoethanol in SDS 
prior to electrophoresis in a 7.5% SDS gel. Panel A, Coomassie  Blue- 
stained protein of 12'I-PDGF-AB/a2M that was denatured (lane 1 ) or 
reduced (lane 2); arrow ( a )  indicates a2M  subunit in lane 1. Autora- 
diography of lane 1 shows that  human "'I-PDGF-AB  was dissociated 
from the a2M subunit upon denaturation by SDS and all visible 
radioactivity appears at  -30 kDa (lane 3 ) .  Autoradiography of lane 2 
demonstrates that reduction results in the appearance of a -15-kDa 
monomer of "'I-PDGF-AB (lane 5). Autoradiography of standard 
human 12'I-aZM-methylamine that contained no PDGF following 
denaturation (lane 4 )  or reduction (lane 6 )  was useful in visualizing 
the  subunits of a2M. Panel B, overexposure of lane 1 from Fig. 3 
allowed visualization of some "'I-PDGF-AB bound to  the denatured 
aZM subunit. 
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FIG. 4. Quantitation of "'1-PDGF-BB bound to slow and 
methylamine or plasmin-treated fast azM under nondenatur- 
ing, denaturing, and reducing conditions. 100 pg of human 
(panel A)  or bovine (panel B )  a2M, aZM-methylamine, or a2M- 
plasmin was incubated  with 1 ng "'I-PDGF-BB in 500 pl of binding 
buffer for 24 h at  37 "C, and  then equivalent  aliquots containing  10 
fig of apM were electrophoresed  in  a nondenaturing  (Tris-borate) gel 
or were pretreated with either  SDS  or  SDS-containing 2-mercapto- 
ethanol prior to electrophoresis in a SDS gel. The  amount of lZ51- 
PDGF-BB bound to  either  the  intact (720 kDa) anM on a nondena- 
turing gel (hatched  bars) or bound to -180-kDa a2M  subunits on a 
denatured gel (open  bars) or a reduced gel (solid  bars) was measured 
on a y-counter. See Fig.  3A, lanes 4 and 6 for visualization of the "'1- 
tu,M-methylamine subunits by autoradiography. The data are ex- 
pressed as  the percentage of apM-bound radioactivity  relative to  the 
total  amount of radioactivity excised from the gel (i.e. a2M-bound 
and free "'I-PDGF-BB). 
pH-dependent Release of PDGF from anM-Denaturation 
of the  PDGF.a2M complex by treatment with SDS or 1 M 
acetic acid was shown to release the majority of PDGF bound 
to a2M, and these  harsh  conditions are known to dissociate 
the anM molecule into its subunits. Thus, we studied the 
possible release of PDGF from a2M over a range of "physio- 
logical" pH (7.5-4.0) where the anM molecule remains  intact. 
Recombinant human lz5I-PDGF-BB incubated with bovine 
slow a2M at  pH 7.5 at  37 "C for 24 h formed a high molecular 
weight complex that eluted on a Superose 6 FPLC column at 
the same position as  the plasma-derived human  lZ5I-PDGF- 
asM (see Fig. 1). By lowering the  pH of solutions  containing 
PDGF. anM complexes with acetic acid for 1 h  prior to loading 
onto  the Superose 6 column, a  pH-dependent decrease in lZ5I- 
PDGF-BB bound to bovine anM was demonstrated (Fig. 5). 
The anM retained its tetrameric (-725 kDa) structure across 
this  pH range, and  the amounts of anM that eluted at  this 
high molecular mass were equivalent as determined by protein 
absorbance (280 nm). The  quantity of lz5I-PDGF-BB bound 
to  a2M, i.e. isolated from the  PDGF. anM complex on  the gel 
filtration column, decreased -50% as  the  pH was decreased 
from 7.5 to 4.0 (Fig. 5). At pH less than 4.0, the a2M was 
denatured and migrated as  subunits with molecular mass >440 
kDa. 
Time  Course of lZ5I-PDGF-BB. a2M Association and Disso- 
ciation-The time course of association of '251-PDGF-BB with 
a Z M  and  the subsequent dissociation of '251-PDGF-BB from 
the purified lZ5I. PDGF-BB . a2M complex was investigated at 
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FIG. 5. pH-dependent dissociation of "'I-PDGF-BB from 
a z M .  After bovine slow azM (100 pg) was incubated with 1 ng of lZ51- 
PDGF-BB  in 500 pl of binding  buffer  for 24 h  (37 "C, pH 7.4), the 
pH was lowered by titrating parallel incubations with 1 M acetic  acid. 
After  reaching the desired pH,  the  samples were left a t  25  "C for 1 h 
and  then loaded onto a Superose 6 FPLC  and  the lZ51.PDGF.aZM 




FIG. 6. Time course of association and dissociation between 
"'I-PDGF-BB and a z M .  Panel A, to measure  association of radi- 
olabeled PDGF with its binding protein, slow bovine azM (100 pg) 
was incubated at  increasing  time  points (30  min to 24 h)  at 37  "C in 
0.5 ml of binding buffer, pH 7.4, with '*'I-PDGF-BB (1 ng = -26,000 
cpm) prior to isolating '2sI.PDGF-BB-azM complex by FPLC gel 
filtration chromatography as described under "Materials and  Meth- 
ods." The  amount of radioactivity  bound to  azM in the 20-28-min 
elution zone of the gel filtration column  (see Fig. 1) was pooled for 
each  time  point. At equilibrium binding (>4 h), approximately half 
of the radiolabeled PDGF was bound  to aZM under  these conditions. 
Panel B, dissociation of "'1. PDGF-BB from lZ51. PDGF-BB. azM 
complex was determined by incubating  lZ5I-PDGF-BB with aZM for 
24 h as shown  in panel A, then  incubating  the isolated lZ5I.PDGF- 
BB.aZM complex for increasing time prior to FPLC separation. 
Again, the 20-28 min elution zone was pooled and radioactivity 
quantitated by y-counting. An equilibrium of bound to free '"1- 
PDGF-BB was reached by 6 h; i.e. approximately half of the  PDGF 
dissociated by this  time point. 
PDGF-BB (2 ng/ml) were incubated at various time  points 
(30 min to 24 h)  at 37 "C in 0.5 ml of binding buffer prior to 
loading onto a Superose 6 FPLC column. The  a2M peak zone 
(20-28 min) was  pooled and bound lZ5I-PDGF-BB quantitated 
by y-counting as demonstrated in Fig. 1. The association time 
course showed that PDGF-BB bound a2M with a tIl2 = -1 h, 
and equilibrium was reached at  -4 h (Fig. 6A). Of the  total 
amount of free lZ5I-PDGF-BB added to  the binding buffer (1 
ng = 25,000-27,000 cpm), approximately half of this radioli- 
gand bound to a2M (-12,000-14,000 cpm) after 24 h of 
incubation.  Identical  aliquots of lZ5I-PDGF-BB. a2M complex 
isolated by FPLC  after 24 h of incubation (the end  point on 
Fig. 6A) were allowed to further incubate for various time 
points (0-24 h)  at 37 "C to measure the  extent of lZ51-PDGF- 
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BB dissociation at  pH 7.4. Under these conditions, 50-60% 
of the bound 12'II-PDGF-BB dissociated from a2M ( t1/2 = -2.5 
h) and  an equilibrium was reached by  -6 h (Fig. 6B). 
PDGF Remains Bound to a2M following Proteolytic Conver- 
sion to the Fast Form-In order to determine whether or  not 
PDGF would  be released from slow a2M during the proteolytic 
conversion of the a2M from  slow to  fast by trypsin, recombi- 
nant human '251-PDGF-BB  complexed to bovine slow  a2M at 
pH 7.5 was treated with a 4 1  molar excess (trypsin/azM) for 
20 min prior to nondenaturing gel electrophoresis. Autoradi- 
ography of the 1251. PDGF-BB a2M complex before and  after 
trypsin exposure showed that  this proteolytic treatment con- 
verted the  a2M  to  the electrophoretically fast form, but  the 
12'II-PDGF-BB remained bound to  the trypsin-activated a2M 
(Fig. 7). 
Competition of PDGF Isoforms and Other Cytokines for 1251- 
PDGF-BB Binding to a2M-The three different isoforms of 
PDGF were tested for competitive binding to a2M to evaluate 
the capacity of this binding protein to potentially modulate 
the activity of all of the PDGF dimers. Human recombinant 
"'I-PDGF-BB (2 ng/ml) and bovine a2M (200 pg/ml) were 
incubated in the absence or presence of an excess of nonra- 
dioactive PDGF-AA,  -AB, or -BB (8 pg/ml) for 24 h at  37  "C. 
All three nonradioactive isoforms inhibited the majority of 
l2'1-PDGF-BB binding as determined by a decrease in the 
radioactivity associated with the slow bovine a2M peak on the 
Superose 6 FPLC column  (Fig. 8). The same experiment was 
performed using fast, methylamine-modified, a2M. Impor- 
tantly, several other cytokines that have been reported to 
bind a2M (i.e. bFGF, IL-10, IL-6, TNF-a, TGF-01, and  TGF- 
p2) were tested for their ability to compete with the I2'I- 
PDGF-BB for binding to both slow and  fast a2M. The column 
fractions containing the PDGF.a2M complex (10-30 min 
elution time) were  pooled and counted for radioactivity. Non- 
radioactive PDGF-AA, -AB, and -BB all inhibited complex 
formation between  '251-PDGF-BB and  a2M or 1251-PDGF-BB 
and a2M-methylamine by  65-80% compared to control treat- 
ments  that received no excess  isoform  (Fig. 9). IL-10, IL-6, 
bFGF, TNF-a, TGF-01, and  TGF-02 each at  an excess con- 
centration (8 pg/ml) did not  inhibit the binding of 12'I-PDGF- 
BB to slow a2M. TGF-01 inhibited complex formation be- 
tween '251-PDGF-BB and a2M-methylamine by as much as 
50%, while TGF-(32 inhibited this  interaction by only 10%. 
IL-6 and bFGF inhibited '"I-PDGF-BB binding to a2M- 
methylamine 30-35%,  while IL-10 and  TNF-a had negligible 
inhibitory effects on this complex formation. Bovine a2M  and 
UX-S 
'F 
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FIG. 7. Autoradiography of 121-PDGF-BB bound to a2M 
before and after conversion of slow bovine a2M to the  fast 
form by trypsin treatment. Slow a2M (100 pg) was incubated with 
"'I-PDGF-BB (1 ng) in 500 pl of binding buffer for 24 h at  37 "C. 
Slow a2M was converted to  the  fast form by treatment with trypsin 
for 20 min at  25 "C as described under "Materials and Methods." 
cu2M-trypsin complexes were purified by Superose 6 FPLC. 1 2 s I -  
PDGF-BB.a2M complexes were loaded onto 5% Tris-borate (non- 
denaturing) gels and electrophoresed as described under "Materials 
and Methods." 
elution time (min) 
FIG. 8. Superose 6 FPLC chromatography demonstrating 
competition of human recombinant PDGF-AA, -AB, and -BB 
dimers for "'I-PDGF-BB binding to slow bovine a z M .  ""I- 
PDGF-BB (1 ng) was  mixed with 100 pg of arM in 500 pl of Ham's 
F-12 binding buffer with HEPES, CaCI2, and 0.25%  BSA, pH 7.4,  in 
the absence (open circles)  or presence of 5 pg  of nonradioactive human 
recombinant PDGF-AA (open triangles), -AB  (closed triangles), or - 
BB (closed  circles) for 24 h at 37  "C prior to loading chromatography 
in phosphate-buffered saline, pH 7.4. anM eluted between 20-28 min 
(see Fig. 1 for immunoreactive profile). All three nonradioactive 
PDGF isoforms inhibited the formation of the  lZsII-PDGF-BB.a~M 
complex by  -70% (see Fig. 5). Arrows indicate molecular mass 
markers: 1, blue dextran (V,,); 2, thyroglobulin (669 kDa); 3, apofer- 
ritin (440 kDa); 4, @-amylase (200 kDa); 5, BSA (66 kDa); 6, carbonic 
anhydrase (29 kDa); and 7, cytochrome c (12.4 kDa). 
FIG. 9. Competition of the known a2M-binding cytokines 
for recombinant "'I-PDGF-BB binding to slow bovine a p M  
and fast azM-methylamine. '2sII-PDGF-BB (1 ng) was  mixed with 
100 pg  of either slow bovine arM (hatched bars) or arM-methylamine 
(hatched bars)  in binding buffer in the absence or presence of 5 pg  of 
nonradioactive cytokine. The amount of radioactivity bound to a2M 
in the 10-30-min elution zone of the gel filtration column (see Fig. 4) 
was pooled for each column run. None of the cytokines tested, other 
than  the  PDGF isoforms, competed for slow a2M, while bFGF, IL-6, 
and  TGF-01 prevented complex formation between PDGF-BBIazM 
30-50%. Inactivation of the proteinase binding capacity of the slow 
a2M by methylamine was measured by the trypsin binding assay 
described under "Materials and Methods" (inset); closed circles  show 
that slow arM possesses trypsin binding activity that is proportional 
to  an increase in absorbance, while methylamine-activated a2M (open 
circles) does not bind trypsin. 
a2M-methylamine bound approximately equivalent amounts 
of '251-PDGF-BB on the gel filtration column, a result similar 
to  that obtained with human "'I-PDGF-AB binding to human 
a2M and a2M-methylamine on a nondenaturing gel (Fig. 2). 
Bovine a2M and a2M-methylamine were not run on a non- 
denaturing gel to  test for differences in electrophoretic migra- 
tion because, unlike human a2M-methylamine, bovine  a2M- 
methylamine does not migrate as a fast form in a nondena- 
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turing gel (27). For this reason, the complete conversion of 
bovine a2M to a2M-methylamine was determined by the 
inability of the methylamine-treated azM to bind and  thus 
inactivate  trypsin (Fig. 9).  Trypsin  that is trapped within the 
a2M molecule is still able to react with small molecules such 
as  the BAPNA reagent (50), producing a yellow product that 
increases in proportion to the amount of slow a2M  in  the 
reaction  mixture (Fig. 9). These data demonstrated that meth- 
ylamine treatment inhibited the trypsin binding capacity of 
bovine slow a2M. 
DISCUSSION 
Earlier studies on plasma-derived PDGF introduced the 
concept that  this growth factor forms covalent bonds with its 
binding protein, a2M (17, 18). In  the process of isolating and 
purifying PDGF from plasma and macrophage supernatants, 
we and others observed that  it was necessary to acidify these 
biological fluids in order to  separate  the  PDGF from its higher 
molecular weight-binding proteins before the growth factor 
could be detected by immunoassay or receptor assay (16, 19). 
The principal PDGF-binding proteins in these fluids were 
identified as a-macroglobulins and  they were found to  inhibit 
the binding of PDGF to either its cell-surface receptor or 
anti-PDGF antibodies, presumably by masking the receptor 
and antibody recognition site on the growth factor  (19). The 
observation that  PDGF could be detected after acidification 
suggested that  at least  a  portion of the  PDGF complexed to 
a2M was bound noncovalently. The issue of covalent versus 
noncovalent binding of PDGF  to a2M is key to understanding 
the biological role(s) that  this binding protein could serve in 
affecting the growth promoting activity of this cytokine. For 
example, aZM  has been proposed as a clearance protein for 
PDGF released into  the circulation following platelet  degran- 
ulation and  the  PDGF.a2M complex could be cleared in the 
liver via a2M receptors on hepatocytes (52). In extravascular 
tissues, macrophages, among other cell types, produce PDGF- 
like molecules and azM (19, 53, 54), and the proliferative 
response of fibroblasts to  PDGF may  be inhibited or enhanced 
by a2M, depending on  whether it is in the slow form or the 
fast receptor-recognized conformation (15). Thus,  azM could 
serve as a clearance pathway for PDGF in the circulation and 
in extravascular tissues, but also as a positive or negative 
regulator of growth factor activity. We postulated that  the 
control of PDGF-stimulated growth by a2M likely involves 
the release of the growth factor from this binding protein, 
allowing PDGF to bind to its own receptor and trigger a 
mitogenic response (15). For this reason, the observation that 
the majority of the PDGF is bound to azM noncovalently 
(Figs. 3 and 4) and the demonstration that approximately 
50% this growth factor can be released from its binding 
protein by lowering the  pH of the incubation medium from 
7.5 and 4.0 (Fig. 5) or in  a  time-dependent manner at  pH 7.4 
(Fig. 6)  are  consistent  with  our hypothesis that  PDGF binding 
to  azM is reversible. Such  information is basic to our  under- 
standing of the mechanism(s) by which the binding protein 
influences cytokine activity. 
Human  lZ5I-PDGF-AB and recombinant  human  lZ5I-PDGF- 
BB both bound human or bovine slow azM,  as well as fast 
a2M  that was prepared by reaction with either methylamine, 
plasmin, or trypsin. All three recombinant PDGF isoforms 
were observed to compete for lZ5I-PDGF-BB binding to either 
a2M or a2M-methylamine, suggesting that these isoforms all 
bind to a similar site on the azM molecule and  that conversion 
from the slow to fast conformation by methylamine does not 
alter PDGF isoform binding. Indeed, azM  and  azM-methyla- 
mine that had been incubated with radiolabeled PDGF  and 
then isolated by nondenaturing gel electrophoresis were found 
to contain approximately equivalent amounts of human lZ5I- 
PDGF-AB or human  recombinant  lZ5I-PDGF-BB. It will be 
of interest  to determine  whether or not  the biological activities 
of PDGF-AA, -AB, and -BB are modulated by azM in a 
similar manner. Interestingly, the lZ5I-PDGF-BB remained 
bound to bovine a2M  after  the  lZ5I-PDGF-BB.  aZM complex 
was treated with an excess of trypsin to convert the  a2M to 
fast form (Fig. 7). Thus, proteinases  apparently do not dis- 
place PDGF bound to  azM,  and these data suggest that  a2M 
could serve to protect PDGF from proteolytic degradation. 
Such a role for azM  has been suggested for IL-6, which is 
inactivated by trypsin, but retains IL-6-like activity in the 
presence of trypsin when complexed to aZM (46). These 
observations also suggest that  PDGF  and IL-6 interact with 
azM by a mechanism different from that of proteinases and 
primary amines. 
The  PDGF.  azM complex could provide a readily obtainable 
source of PDGF in uiuo since the growth factor can be removed 
under physiological conditions i n  vitro. Kinetic studies 
showed that under  conditions which are similar to those found 
in plasma, i.e. high [a2M]  and relatively low [PDGF], half of 
the  PDGF bound a2M in  a  time-dependent  manner reaching 
equilibrium after 4  h at 37 "C and subsequently half of this 
azM-bound  PDGF dissociated from isolated PDGF/a2M com- 
plex more slowly and reached a new equilibrium after  6  h at  
37 "C (Fig. 6). A calculation of the  rate  constants for associ- 
ation ( kl) and dissociation ( k2), which must assume an excess 
of radioligand over receptor (or binding protein), were not 
performed on  these  kinetic data due to  the low molarity of 
lZ5I-PDGF-BB (6.7 X lo-" M) relative to azM (3 X M); 
i.e. there was likely an excess of binding sites for PDGF. 
Further studies using saturation binding and kinetic  studies 
are in progress to address the relative affinities of PDGF for 
azM versus the  PDGF cell-surface receptor. The time course 
data shown in Fig. 6 for association of lZ5I-PDGF-BB with 
a2M are closely similar to  the time course of lZ5I-bFGF binding 
aZM (44); i.e. low concentrations of both bFGF and  PDGF 
binding to 200 pg/ml aZM reached an equilibrium state  at 
about  4 h. lZ5I-PDGF-BB was released rapidly from the 1251- 
PDGF-BB.a2M complex by lowering the  pH over a physio- 
logical range of 7.4-4.0 (Fig. 5). Such low pH could be en- 
countered within lysozomes following internalization of the 
PDGF.azM complex via the azM receptor. In this case, it 
would  be of interest  to learn  whether or not released PDGF 
(which is acid stable) could then be  recycled to  the cell-surface 
and remain bioactive. Thus,  it is conceivable that  PDGF could 
be dissociated from the  PDGF.  azM complex by either deple- 
tion of unbound PDGF via internalization by PDGF cell- 
surface receptors (which would favor the release of azM-bound 
PDGF  to establish  a new extracellular equilibrium) or PDGF 
could be released under  conditions where pH is reduced. 
Since several other cytokines bind to a2M we sought to 
establish if these growth factors compete for PDGF binding 
to  azM. Excess concentrations of TGF-Dl,  TGF-82, TNF-a, 
bFGF, IL-1P, and IL-6 were tested for their inhibitory potency 
in  preventing complex formation between lZ5I-PDGF-BB and 
aZM or azM-methylamine. None of these cytokines inhibited 
the binding of Iz5I-PDGF-BB to  the slow form of azM  (Fig. 
9). These  data suggest that  PDGF isoforms could bind to slow 
azM unhindered in  the presence of cytokine mixtures i n  vivo. 
In contrast, some of these cytokines competed for PDGF 
binding to fast azM. TGF-Dl, but not TGF-P2, inhibited 
complex formation between Iz5I-PDGF-BB and a2M-methyl- 
amine by -50%. While both TGF-Pl  and TGF-P2 bind to 
fast  a2M (42), it is conceivable that these two factors have 
PDGF Isoforms Binding a2-Macroglobulin 12843 
differing affinities for a2M or bind to different sites  on the 
a2M molecule. Thus,  the TGF-81-binding site  on  the  fast a2M 
could overlap or allosterically modulate the PDGF-binding 
site. Similarly, IL-6 and bFGF inhibited complex formation 
between 1261-PDGF-BB and a2M-methylamine by -20-30%, 
which  could  suggest  some overlap or allosteric hinderance by 
PDGF and these cytokines binding simultaneously to fast 
a2M.  TGF-81 has been reported to inhibit the binding of  1251- 
bFGF binding to a2M, while PDGF does not compete for this 
interaction (44). It is conceivable that certain azM-binding 
cytokines, such as TGF-81 and bFGF, could mediate the 
release of PDGF from the fast form of a2M,  but  not  the slow 
form. Other cytokines apparently do not interfere with PDGF 
binding to  a2M. For example, TNF-a binds fast  a2M-meth- 
ylamine (43) but did not  inhibit the formation of the PDGF- 
BB-a2M-methylamine complex (Fig. 9). Such interactions 
between these cytokines and  the two forms of a2M are likely 
to  be  complex and require further study. 
A variety of growth-promoting cytokines, including PDGF, 
are likely to be involved in the processes of normal tissue 
maintenance and repair, and  their  abberant expression may 
well be linked to pathogenic disorders such as pulmonary 
fibrosis and atherogenesis that are characterized by an  in- 
crease in cell proliferation and extracellular matrix production 
(7). A growing number of studies suggest that  a2M could play 
a role in modulating the biological activity, clearance, and 
degradation of these cytokines in  either the circulation or  in 
extravascular tissues (36-48). Because a2M also serves as a 
proteinase inhibitor and since proteinases irreversibly convert 
a2M  to a fast or receptor-recognized form, this adds another 
layer of complexity to the problem of understanding the 
mechanisms by  which a number of cytokines interact with a 
common binding protein. Proteinases  apparently  are capable 
of “turning  on” the modulatory effects that  a2M has for some 
cytokines in at least two different ways: 1) cytokines such as 
TNF-a (43) and  IL-18 (45) preferentially bind fast  a2M (42) 
and thus the activity of these cytokines would not be expected 
to be directly regulated by  slow form a2M,  and 2) PDGF binds 
both native and proteinase-reacted forms and  a2M converted 
to the  fast form by methylamine synergistically enhances the 
growth promoting activity of PDGF, while the slow form 
inhibits PDGF-stimulated growth (15). It is presently unclear 
whether or not a2M-proteinase complexes potentiate or in- 
hibit the growth promoting activity of the different PDGF 
isoforms, and  this is the subject of ongoing studies. Under- 
standing the interactions between the network of proteinases, 
a2M, and growth factors which bind a2M will  be fundamental 
to  our knowledge of cytokine function in vivo. 
In summary, the majority of the  PDGF-a2M association is 
noncovalent and all three  PDGF isoforms (-AA, -AB, and - 
BB) bind similarly to a2M.  PDGF binds to slow and  fast a2M 
and  the slow to fast conversion by trypsin does not dissociate 
bound PDGF. PDGF-BB dissociates slowly from isolated 
PDGF. a2M complex ( t l I 2  = 2-3 h) at pH 7.4 and reaches an 
equilibrium state after 6 h. Furthermore, a decrease in pH 
from 7.4 to 4.0 causes a rapid, progressive release of PDGF 
from aZM. Because PDGF binding to  a2M is reversible, a2M 
could release PDGF near the cell surface in close proximity 
to  its own receptor. 
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